Skip to main content
. 2024 Mar 10;13(17):2304626. doi: 10.1002/adhm.202304626

Figure 7.

Figure 7

Lipid‐based nanocarriers for ocular posterior drug delivery. a) Schematic illustration of the lipid nanocapsule and therapeutic concept to prevent ROP. Reproduced under the terms of the CC‐BY‐NC.[ 151 ] Copyright 2022, American Association for the Advancement of Science. b) Schematic illustration of the synthesis and co‐delivery of microRNA‐150 and quercetin of Que/mR150‐NSLNs for treating CNV. Reproduced with permission.[ 142 ] Copyright 2023, Elsevier. c) Schematic illustration of the synthesis and sustained retinal drug delivery of Bor/RB‐M@TRG, which is capable of sustainedly releasing Bor/RB‐M to the RPE, thereby collaboratively inhibiting the formation of CNV driven by the “angiogenesis‐oxidative stress” loop. Reproduced under the terms of the CC‐BY.[ 153 ] Copyright 2023, The Authors, published by Springer Nature.